Clinical Trials | May 28, 2024
Ascentage releases results from multiple clinical studies of its lead drug candidates
These abstracts report on the company's three lead drug candidates, including olverembatinib
These abstracts report on the company's three lead drug candidates, including olverembatinib
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Establishing Asymchem’s first manufacturing footprint in Europe
Subscribe To Our Newsletter & Stay Updated
